Boston Scientific (BSX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.86
- EPS estimate
- $0.83
- EPS surprise
- +3.90%
- Revenue surprise
- +1.44%
- Revenue
- $5.4B
- Revenue estimate
- $5.4B
- Reported
- Jul 29, 2026
Boston Scientific reported Q2 2026 results on July 29, 2026. Earnings per share came in at $0.86, ahead of the $0.83 estimate by 3.90%. Revenue was $5.4 billion, about 1.4% above the consensus, which also rounded to $5.4 billion. Compared with Q2 2025, EPS rose about 15% from $0.75 and revenue rose about 5.9% from $5.1 billion.
Annual EPS rose every year in the table, from $1.71 in 2022 to $2.05 in 2023, $2.51 in 2024 and $3.05 in 2025. That is an increase of about 78% over three years, close to 21% a year. The first half of 2026 adds up to $1.66, about 11% more than the same period a year earlier. Q2 2026 set the highs in the table at $0.86 per share and $5.4 billion in revenue, up from $2.9 billion in Q3 2021. Over the last 20 quarters, Boston Scientific beat the EPS estimate 18 times. The only misses were Q3 and Q4 2022.
Boston Scientific reported Q3 between October 22 and October 27 in each of the past five years. That points to late October 2026 for the next report. It will show whether the growth seen in recent quarters continues.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | $0.83 | $0.86 | +3.90% | $5.4B | SEC |
| Q1 2026 | Apr 22, 2026 | $0.79 | $0.80 | +1.51% | $5.2B | SEC |
| Q4 2025 | Feb 4, 2026 | $0.78 | $0.80 | +2.56% | $5.3B | SEC |
| Q3 2025 | Oct 22, 2025 | $0.71 | $0.75 | +5.09% | $5.1B | SEC |
| Q2 2025 | Jul 23, 2025 | $0.73 | $0.75 | +3.38% | $5.1B | SEC |
| Q1 2025 | Apr 23, 2025 | $0.67 | $0.75 | +11.46% | $4.7B | SEC |
| Q4 2024 | Feb 5, 2025 | $0.66 | $0.70 | +6.53% | $4.6B | SEC |
| Q3 2024 | Oct 23, 2024 | $0.59 | $0.63 | +7.09% | $4.2B | SEC |
| Q2 2024 | Jul 24, 2024 | $0.58 | $0.62 | +6.27% | $4.1B | SEC |
| Q1 2024 | Apr 24, 2024 | $0.51 | $0.56 | +9.03% | $3.9B | SEC |
| Q4 2023 | Jan 31, 2024 | $0.51 | $0.55 | +7.23% | $3.7B | SEC |
| Q3 2023 | Oct 26, 2023 | $0.48 | $0.50 | +4.76% | $3.5B | SEC |
| Q2 2023 | Jul 27, 2023 | $0.49 | $0.53 | +8.16% | $3.6B | SEC |
| Q1 2023 | Apr 26, 2023 | $0.43 | $0.47 | +8.60% | $3.4B | SEC |
| Q4 2022 | Feb 1, 2023 | $0.47 | $0.45 | −4.60% | $3.2B | SEC |
| Q3 2022 | Oct 26, 2022 | $0.44 | $0.43 | −2.56% | $3.2B | SEC |
| Q2 2022 | Jul 27, 2022 | $0.42 | $0.44 | +3.95% | $3.2B | SEC |
| Q1 2022 | Apr 27, 2022 | $0.38 | $0.39 | +1.35% | $3.0B | SEC |
| Q4 2021 | Feb 2, 2022 | $0.44 | $0.45 | +2.51% | $3.1B | SEC |
| Q3 2021 | Oct 27, 2021 | $0.40 | $0.41 | +3.69% | $2.9B | SEC |
Quarterly revenue
Frequently asked questions
When did Boston Scientific (BSX) last report earnings?
Boston Scientific last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did BSX beat earnings estimates?
Yes. Boston Scientific reported EPS of $0.86 for Q2 2026 against a $0.83 estimate — a 3.90% beat.
How much revenue did BSX report last quarter?
Boston Scientific reported $5.4B in revenue for Q2 2026, against a consensus estimate of $5.4B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.